Key result
Positron emission tomography revealed significantly lower oxygen consumption in hypertrophied versus nonhypertrophied myocardium (0.044 vs 0.060/min, p<0.0001) despite similar blood flow.
Why the study?
Does positron emission tomography reveal differences in regional myocardial blood flow and metabolism in hypertrophied myocardium of patients with hypertrophic cardiomyopathy?
Case-Control (n=29)
Does positron emission tomography reveal differences in regional myocardial blood flow and metabolism in hypertrophied myocardium of patients with hypertrophic cardiomyopathy?
Absolute Event Rate: 0.044% vs 0.06%
p-value: p=<0.0001
Hypertrophied myocardium in HCM patients exhibits decreased oxidative metabolism and glucose utilization despite preserved perfusion, suggesting a primary metabolic defect.
The underlying pathophysiology of hypertrophic cardiomyopathy (HCM) is still unclear. positron emission tomography is a suitable and promising technique for the detection of possible metabolic consequences of the disease. To assess regional myocardial blood flow and metabolism, 19 asymptomatic or only mildly symptomatic patients with HCM and 10 normal control subjects were studied using carbon-11 acetate and fluorine-18-labelled deoxyglucose (FDG) as tracers of myocardial blood flow (Ao), oxygen consumption (k), and exogenous glucose utilization. In the patients, regional Ao in the hypertrophied septum and apex (H) was similar to that in the nonhypertrophied free wall (N) (91.3 +/- 3.9% vs 92.9 +/- 3.1%; p = NS). However, the k values were significantly lower in H than in N (0.044 +/- 0.012 vs 0.060 +/- 0.016/min, p < 0.0001). The k value in N and normal control subjects (0.062 +/- 0.013) was similar. Postprandial FDG uptake was lower in H than in N (70 +/- 16 vs 91 +/- 7%; p < 0.0001) in 16 patients and slightly higher in 3 patients. Fasting FDG study showed increased FDG uptake in H in 3 out of 13 patients, suggesting a disorder of the myocardial microvascular circulation. A relative decrease in hypertrophied septal and apical oxidative metabolism and glucose utilization without any corresponding perfusion defect could reflect abnormal regional aerobic metabolism in the disproportionately thickened myocardium in patients with HCM. This suggests that a primary myocardial metabolic defect might be present in patients with HCM.
No takes yet. Share an insight, caveat, or question.
Ishiwata et al. (1997) conducted a case-control in Hypertrophic Cardiomyopathy (n=29). Positron emission tomography with carbon-11 acetate and FDG vs. Normal control subjects and nonhypertrophied myocardium was evaluated on Oxygen consumption (k) in hypertrophied vs nonhypertrophied myocardium (p=<0.0001). Positron emission tomography revealed significantly lower oxygen consumption in hypertrophied versus nonhypertrophied myocardium (0.044 vs 0.060/min, p<0.0001) despite similar blood flow.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: